GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials.

Tsapas A, Karagiannis T, Avgerinos I, Liakos A, Bekiari E

Diabetes research and clinical practice15 Jun 2021Cited by 22 (Europe PMC)

PMID34144086DOI10.1016/j.diabres.2021.108921PepBankPUB-34144086

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, GLP-1 receptor agonists reduced major adverse cardiovascular events by 13% compared with placebo.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs lowered major heart and blood vessel events by 13% compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseMajor adverse cardiovascular events
Study
n = 43,456
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.87 NA
MACE
Source sentences
Summary
GLP-1 RAs reduced MACE by 13% (HR 0.87, 95% CI 0.82-0.93)
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE and EMBASE through May 5, 2021 for randomized, placebo-controlled, cardiovascular outcomes trials of GLP-1 RAs in patients with type 2 diabetes that reported cardiovascular or mortality outcomes by baseline metformin use.
Summary · context
We included 4 trials (43,456 patients) assessing albiglutide, dulaglutide, exenatide once weekly and liraglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3414408601
02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes taking metformin at baseline, GLP-1 receptor agonists reduced major adverse cardiovascular events compared with placebo.
In plain wordsIn adults with type 2 diabetes who took metformin, GLP-1 drugs lowered major heart and blood vessel events compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseMajor adverse cardiovascular events with metformin at baseline
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.91 NA
with metformin
Source sentences
Summary
consistent in both subgroups (HR 0.91, 95% CI 0.85-0.97 and HR 0.80, 95% CI 0.72-0.90 with and without metformin, respectively
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE and EMBASE through May 5, 2021 for randomized, placebo-controlled, cardiovascular outcomes trials of GLP-1 RAs in patients with type 2 diabetes that reported cardiovascular or mortality outcomes by baseline metformin use.
Summary · context
We included 4 trials (43,456 patients) assessing albiglutide, dulaglutide, exenatide once weekly and liraglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3414408602
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes not taking metformin at baseline, GLP-1 receptor agonists reduced major adverse cardiovascular events compared with placebo.
In plain wordsIn adults with type 2 diabetes who did not take metformin, GLP-1 drugs lowered major heart and blood vessel events compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseMajor adverse cardiovascular events without metformin at baseline
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
HR
0.8 NA
without metformin
Source sentences
Summary
consistent in both subgroups (HR 0.91, 95% CI 0.85-0.97 and HR 0.80, 95% CI 0.72-0.90 with and without metformin, respectively
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE and EMBASE through May 5, 2021 for randomized, placebo-controlled, cardiovascular outcomes trials of GLP-1 RAs in patients with type 2 diabetes that reported cardiovascular or mortality outcomes by baseline metformin use.
Summary · context
We included 4 trials (43,456 patients) assessing albiglutide, dulaglutide, exenatide once weekly and liraglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3414408603
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, GLP-1 receptor agonists had a favorable effect on cardiovascular mortality, regardless of baseline metformin use.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs had a favorable effect on deaths from heart and blood vessel causes, with or without metformin.
Peptide
Liraglutide
Outcome
DecreaseCardiovascular mortality
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Presence of metformin at baseline did not affect the overall favorable effect of GLP-1 RAs both on cardiovascular and all-cause mortality.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE and EMBASE through May 5, 2021 for randomized, placebo-controlled, cardiovascular outcomes trials of GLP-1 RAs in patients with type 2 diabetes that reported cardiovascular or mortality outcomes by baseline metformin use.
Summary · context
We included 4 trials (43,456 patients) assessing albiglutide, dulaglutide, exenatide once weekly and liraglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3414408604
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, GLP-1 receptor agonists had a favorable effect on all-cause mortality, regardless of baseline metformin use.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs had a favorable effect on deaths from any cause, with or without metformin.
Peptide
Liraglutide
Outcome
DecreaseAll-cause mortality
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Mortality · Cardiovascular
Source sentences
Summary
Presence of metformin at baseline did not affect the overall favorable effect of GLP-1 RAs both on cardiovascular and all-cause mortality.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE and EMBASE through May 5, 2021 for randomized, placebo-controlled, cardiovascular outcomes trials of GLP-1 RAs in patients with type 2 diabetes that reported cardiovascular or mortality outcomes by baseline metformin use.
Summary · context
We included 4 trials (43,456 patients) assessing albiglutide, dulaglutide, exenatide once weekly and liraglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3414408605
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, GLP-1 receptor agonists had a neutral effect on stroke, irrespective of metformin use.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs had no clear effect on stroke, with or without metformin.
Peptide
Liraglutide
Outcome
No significant changeStroke
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Finally, subgroup meta-analyses suggested that GLP-1 RAs had a neutral effect on stroke, myocardial infarction and hospitalization for heart failure, irrespective of metformin use at baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE and EMBASE through May 5, 2021 for randomized, placebo-controlled, cardiovascular outcomes trials of GLP-1 RAs in patients with type 2 diabetes that reported cardiovascular or mortality outcomes by baseline metformin use.
Summary · context
We included 4 trials (43,456 patients) assessing albiglutide, dulaglutide, exenatide once weekly and liraglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3414408606
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, GLP-1 receptor agonists had a neutral effect on myocardial infarction, irrespective of metformin use.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs had no clear effect on heart attacks, with or without metformin.
Peptide
Liraglutide
Outcome
No significant changeMyocardial infarction
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Finally, subgroup meta-analyses suggested that GLP-1 RAs had a neutral effect on stroke, myocardial infarction and hospitalization for heart failure, irrespective of metformin use at baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE and EMBASE through May 5, 2021 for randomized, placebo-controlled, cardiovascular outcomes trials of GLP-1 RAs in patients with type 2 diabetes that reported cardiovascular or mortality outcomes by baseline metformin use.
Summary · context
We included 4 trials (43,456 patients) assessing albiglutide, dulaglutide, exenatide once weekly and liraglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3414408607
08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adults with type 2 diabetes, GLP-1 receptor agonists had a neutral effect on hospitalization for heart failure, irrespective of metformin use.
In plain wordsIn adults with type 2 diabetes, GLP-1 drugs had no clear effect on hospital stays for heart failure, with or without metformin.
Peptide
Liraglutide
Outcome
No significant changeHospitalization for heart failure
Study
n: not reported in source
Comparator
Placebo
Analysis
Secondary
Outcome group
Heart function · Cardiovascular
Source sentences
Summary
Finally, subgroup meta-analyses suggested that GLP-1 RAs had a neutral effect on stroke, myocardial infarction and hospitalization for heart failure, irrespective of metformin use at baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
We searched MEDLINE and EMBASE through May 5, 2021 for randomized, placebo-controlled, cardiovascular outcomes trials of GLP-1 RAs in patients with type 2 diabetes that reported cardiovascular or mortality outcomes by baseline metformin use.
Summary · context
We included 4 trials (43,456 patients) assessing albiglutide, dulaglutide, exenatide once weekly and liraglutide.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3414408608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.